miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia

Martina Pigazzi1, Elena Manara, Emma Baron

  • 1Laboratory of Hematology-Oncology, Department of Pediatrics, University of Padova, Padova, Italy. martina.pigazzi@unipd.it

Cancer Research
|March 5, 2009
PubMed

Insights

MicroRNAs regulate gene expression; miR-34b deficiency contributes to CREB overexpression in leukemia by targeting CREB. This epigenetic mechanism offers new therapeutic strategies for myeloid transformation.

Area of Science:

  • Molecular Biology
  • Epigenetics
  • Cancer Biology

Background:

  • Cyclic AMP-responsive element binding protein (CREB) is overexpressed in leukemia, but the mechanism is unclear.
  • MicroRNAs (miRNAs) are key negative gene regulators.
  • This study investigates miRNAs' role in CREB overexpression.

Purpose of the Study:

  • To identify miRNAs targeting CREB.
  • To elucidate the mechanism of CREB overexpression in leukemia.
  • To explore the therapeutic potential of miR-34b.

Main Methods:

  • miRNA identification and screening.
  • Quantitative PCR and in vitro assays.
  • Reverse-phase protein array and epigenetic analysis.
  • Correlation study in pediatric acute myeloid leukemia patients.

Main Results:

  • miR-34b was significantly downregulated in leukemia cell lines.
  • Exogenous miR-34b directly targeted CREB mRNA, reducing protein levels.
  • miR-34b restoration inhibited cell proliferation and altered CREB target gene expression.
  • Epigenetic silencing (promoter methylation) of miR-34b was observed in leukemia cells.
  • Inverse correlation between miR-34b and CREB expression confirmed in patients.

Conclusions:

  • miR-34b directly targets and represses CREB.
  • Epigenetic silencing of miR-34b contributes to CREB overexpression in leukemia.
  • miR-34b acts as a tumor suppressor, offering potential therapeutic avenues for myeloid leukemia.